Scinai Immunotherapeutics Ltd. — Form F-1
Filed September 24, 2026 · analyzed by the Registration Agent
F-1
▼ Likely negative
significance 72/100
What the filing says
Scinai Immunotherapeutics (Israeli biotech, $16.7M market cap) filed F-1 to register resale of up to 2,706,450 ADSs by YA II PN, Ltd. under a Standby Equity Purchase Agreement dated September 10, 2025. YA committed to purchase up to $15.0M of ADSs at 97% of lowest 3-day VWAP; to date $1.1M purchased (473,275 ADSs issued). Company received 3,546 Commitment Shares as upfront consideration. Registration covers remaining ~$13.9M undrawn commitment; actual proceeds depend on stock price at time of sales. Company will not receive proceeds from YA's resales, only from its own sales to YA if directed.
Why this rating
Massive dilution risk (2.7M ADSs = 67% of current float) relative to tiny $16.7M cap; potential 200%+ shareholder dilution. Nasdaq compliance still fragile (just recovered Sept 2026 after reverse split). Critical liquidity source but extreme downward pressure on share price likely.
Price action (we called it negative)
before filing · preread $1.86 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.